



15W

PATENT
2288-0103PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: XIE, Ya-Gang Conf.: 2498
Appl. No.: 10/735,600 Group: 1641
Filed: December 12, 2003 Examiner: UNASSIGNED
For: METHOD FOR THE DETECTION OF RISK
FACTORS ASSOCIATED WITH MYOCARDIAL
INFARCTION

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 27, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

IV. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
- or
- b. ☒ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)


- ☐ A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. This paper is submitted in triplicate.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Leonard R. Svensson, #30,330

LRS/sd
2288-0103PUS1

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s): ☒ PTO-1449
☒ Documents
☐ Foreign Search Report
☒ Fee
☐ Other:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on: _____

(Date of Deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP



(Signature)

1-27-2005

(Date of Signature)

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

 ATTY. DOCKET NO.
2288-0103PUS1

 APPLICATION NO.
10/735,600

 APPLICANT
XIE, Ya Gang

 FILING DATE
December 12, 2003

 GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 5,620,688		1997-04-15	Reed et al.			
	US 5,766,869		1998-06-16	Arkel et al.			
	US 5,834,223		1998-11-10	Griffin et al.			
	US 5,874,256		1999-02-23	Bertina et al.			
	US 5,910,576		1999-06-08	Bertina et al.			
	US 6,040,147		2000-03-21	Ridker et al.			
	US 6,043,035		2000-03-28	Bertina et al.			
	US 6,083,757		2000-07-04	Griffin et al.			
	US 6,147,078		2000-11-14	Sanderson et al.			
	US 6,183,980	B1	2001-02-06	Siegemund et al.			

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	WO	2,347,247	A3	2000-04-20	CANADA				
	EP	0,200,362	B1	1986-10-12	EP				
	EP	0,201,184	B2	1986-12-17	EP				

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	Amowitz, et al.; (1999) Factor V Leiden is Not a Risk Factor for Myocardial Infarction Among Young Women; Correspondence, pp.1432-1433
	Ardissino, D., et al., (1999) Prothrombotic Genetic Risk Factors in Young Survivors of Myocardial Infarction; Blood; Vol. 94, No. 1, pp. 46-51
	Ariens, R. et al., (2000) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure; Blood; Vol. 96, No. 3, pp. 988-995
	Arruda, V et al., (1998) Prevalence of the prothrombin gene variant 20210 G- A among patients with myocardial infarction; Cardiovascular Research 37, pp. 42-45

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTY. DOCKET NO. 2288-0103PUS1	APPLICATION NO. 10/735,600
	APPLICANT XIE, Ya Gang	
	FILING DATE December 12, 2003	GROUP 1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

	Corral, J. et al., (2001) Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage; Blood, Vol. 97, No. 10, pp. 2979-2982
	Doggen, J.M. et al., (1998) Increased Risk of Myocardial Infarction Associated with Factor V Leiden or Prothrombin 20210A; American Heart Association, Inc. pp. 1037-1041
	Eikkelboom, J.W. et al., (1998) No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease; Thromb-Haemost., 80(6): 878-80
	Faham M and Cox D.R., (1995) A novel in vivo method to detect DNA sequence variation; Genome Res. (5): 474-82.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTY. DOCKET NO. 2288-0103PUS1	APPLICATION NO. 10/735,600
	APPLICANT XIE, Ya Gang	
	FILING DATE December 12, 2003	GROUP 1641
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	Gauderman J.W., (2002) Sample Size Requirements for Association Studies of Gene Interaction; American Journal of Epidemiology, Vol.155, No.5, pp.478-484.	
	Huston et al., (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single chain Fv analogue produced in Escherichia coli; Proc Natl Aca Sci, 85(16): 5879-83.	
	Kohler, H.P., et al. (1998) Association of a common polymorphism in the factor XIII gene with myocardial infarction; Throm-Haemost., 79(1): 8-13.	
	Linfert D.R., et al. (1998) Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia. Conn. Med., 62(9): 519-525.	
	Lung, C.C. and Chan, K.L. (1996) Simplifying 5' RACE in the hunt for full-length cDNAs. Trends in Genetics, 12, 389-391.	
	Mansourati, J., (2000) Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb-Haemost., 83(6): 822-5.	
	Miller S.A., et al., (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research; 16(3): 1215.	
	Poort, (1996) A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis; Blood 88 (10): 3698-3703.	
	Ridker, P.M., et al., (1999) G20210A Mutation in Prothrombin Gene and Risk of Myocardial Infarction, stroke and Venous Thrombosis in a Large Cohort of US Men; Circulation, (8): 999-1004.	
	Rosendaal, (1997) A Common Prothrombin Variant (20210 G to A) Increases the Risk of Myocardial Infarction in young Women; Blood; 90(5) 1747-1750.	
	Russo, C., et al., (2001) G 20210 A Prothrombin Gene Polymorphism and Prothrombin Activity in Subjects with or Without Angiographically Documented Coronary Artery Disease; Circulation, 103 (20): 2436-40.	
	Saiki et al., (1988) Science 239, 487.	
	Sanger (1977) Proc. Natl. Acad. Sci. USA, 74 5463-7.	
	Tetrahedron Letters 22, (1981) 1859-1862.	
	Thrombosis and Homeostasis 78, (1977) 1157-1163.	
	Trumbo, T.A. and Maurer M.C., (2000) Examination Thrombin Hydrolysis of Factor XIII Activation Peptide Segment Leads to a Proposal for Explaining the Cardio protective Effects Observed with the Factor XIII V34L Mutation; The Journal of Biological Chemistry, Vol.275, No. 27, pp.20627-20631.	
EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449		ATTY. DOCKET NO. 2288-0103PUS1	APPLICATION NO. 10/735,600
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT XIE, Ya Gang	
		FILING DATE December 12, 2003	GROUP 1641
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	Trumbo, T.A. and Maurer M.C., (2002) Thrombin Hydrolysis of V29F and V34L Mutants of Factor XIII (28-41) reveals Roles of the P9 and P4 Positions in Factor XIII Activation; Biochemistry, Vol.41, 2859-2868.		
	Van de Water, N. S., et al., (2000) Prevalence of Factor V Leiden and Prothrombin Variant G20210A in Patients Age <50 Years with No Significant Stenoses at Angiography Three to Four Weeks After Myocardial Infarction; Journal of the American College of Cardiology, Vol.36, No.3, pp.717-722.		
	Wagner et al. (1995) Mutation detection using immobilized mismatch binding protein (MutS); Nucl acids res, 23(19): 3944-3948.		
	Ward et al., (1989) Nature 341:544-546.		
	Warner, D.et al., (2001) Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography; Thromb-Haemost, 85(93): 408-11.		
	Wartiovaara, U. et al., (1999) Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish Wartiovaara; U Atherosclerosis, 142(2): 295-300.		
	Weger, M et al., (2003) Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion; 17 (6): 731-4.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			